Business Description
PhaseBio Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7172241090
Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 35.6 | |||||
| 14-Day RSI | 40.74 | |||||
| 6-1 Month Momentum % | -50 | |||||
| 12-1 Month Momentum % | -87.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -7557.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.02 | |||||
| EV-to-EBITDA | 0.02 | |||||
| EV-to-Revenue | -2.98 | |||||
| EV-to-Forward-Revenue | 0.32 | |||||
| Earnings Yield (Greenblatt) % | 5000 | |||||
| FCF Yield % | -15.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PHASQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PhaseBio Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.818 | ||
| EPS (TTM) ($) | -2.13 | ||
| Beta | 2.18 | ||
| Volatility % | 602.02 | ||
| 14-Day RSI | 40.74 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | -87.5 | ||
| 52-Week Range ($) | 0.0001 - 0.0399 | ||
| Shares Outstanding (Mil) | 49.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PhaseBio Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PhaseBio Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
PhaseBio Pharmaceuticals Inc Frequently Asked Questions
What is PhaseBio Pharmaceuticals Inc(PHASQ)'s stock price today?
The current price of PHASQ is $0.00. The 52 week high of PHASQ is $0.04 and 52 week low is $0.00.
When is next earnings date of PhaseBio Pharmaceuticals Inc(PHASQ)?
The next earnings date of PhaseBio Pharmaceuticals Inc(PHASQ) is 2024-05-16 Est..
Does PhaseBio Pharmaceuticals Inc(PHASQ) pay dividends? If so, how much?
PhaseBio Pharmaceuticals Inc(PHASQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers